Breast Cancer Advice. Keep up to date with the latest information and treatment of breast cancer.
A Member of the Healthscout Network
 Printer Friendly  Send to a Friend

Raised Breast Cancer Risk Persists After Combo HRT Stopped

Latest data from Women's Health Initiative points to continued need for mammograms

By Amanda Gardner
HealthDay Reporter

TUESDAY, March 4 (HealthDay News) -- An increased risk of breast cancer lingers after a woman stops taking combination hormone replacement therapy, a new study shows.

The finding, published in the March 5 issue of the Journal of the American Medical Association, was based on data from the landmark Women's Health Initiative (WHI). That trial was halted abruptly in 2002, when it was discovered that postmenopausal women taking combination hormone therapy (estrogen plus progestin) had a higher risk of cardiovascular disease, stroke, blood clots and breast cancer.

Advertisement
Related Stories
 border=
New Screening Catches More Breast Cancers
Breast Cancer Drug Not Tied to Cognitive Decline: Study
Normal Cells May Predict Cancer Virulence
Related Videos
 border=
A Welcome Message from Survivor PJ Hamel
Smother Says "Cut!"
Maryann and Paula
Related Slides
 border=
Breast Cancer
Breast Self-Exam


"Within a couple of years, the [raised] risk for stroke, serious blood clots and heart attack disappears, but so do the benefits to bone," added study author Marcia Stefanick, a professor of medicine at Stanford University. "The concerning issue is the risk for all cancers remains significantly elevated, mostly because of breast cancer."

Stefanick said it wasn't clear if these were new breast cancers or existing tumors that had not been detected while women were still taking hormone therapy. A study in the Archives of Internal Medicine last week found women taking combined hormone therapy for about five years had a higher risk of abnormal mammograms and breast biopsies. This, in turn, may decrease the effectiveness of these methods for detecting breast cancer.

Dr. James Liu, chairman of obstetrics and gynecology at MacDonald Women's Hospital at Case Medical Center, University Hospitals, in Cleveland, emphasized that the results applied only to women taking combination hormone therapy, and that there may indeed be a delay involved. "The good news is that these changes do reverse," he said. "There may be some lag time in the breast risk, but because the breast risk actually increases with age independent of estrogen, women still should continue to have annual surveillance."

Stefanick is chairwoman of the WHI investigator group, and Liu was the principal investigator for the WHI in Cincinnati until 2001.

The current research followed 15,730 of the original WHI participants for an average of three years after the trial ended.

The risk of cardiovascular problems was similar in the HRT and placebo groups (1.97 percent and 1.91 percent, respectively). However, there was a greater risk of overall cancer in the HRT group (1.56 percent of participants) as compared with the placebo group (1.26 percent). Most of this was explained by a heightened risk of breast cancer, the researchers said.

Lung cancer risk was slightly higher but not enough to draw any firm conclusions. "It's not such a big study that you can see all the things you need to see when you look across the population," Stefanick said. "The people who are actually studying cancer across the whole population will start to potentially identify other cancers that are related to the combination therapy."

Death from any cause was 15 percent higher in the HRT group than in the placebo group.

Putting all these factors together, the risks of combined HRT exceed the benefits, the authors stated.

"The really important message for women is they need to get a mammogram if they've stopped using hormones," Stefanick said. "They shouldn't think everything is fine. They need to get a mammogram to make absolutely sure. Once they've stopped the hormones, you have a better chance of detecting them."

Follow-up data in the estrogen-alone arm of the WHI is not yet available.

More information

The National Heart, Lung, and Blood Institute has more on the Women's Health Initiative.

SOURCES: Marcia Stefanick, Ph.D., professor, medicine, Stanford University; James Liu, M.D., chairman, department of obstetrics and gynecology, MacDonald Women's Hospital, Case Medical Center, University Hospitals, Cleveland; March 5, 2008, Journal of the American Medical Association

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 3/4/2008



Disclaimer: The information provided on this website is for educational purposes only and does not serve as a replacement for care provided by your own personal health care team. This website does not render or provide medical advice, and no individual should make any medical decisions or change their health behavior based on information provided here. All pertinent content provided on this website should be discussed with your personal physician to evaluate whether it has any relevance to or impact on your specific condition. Reliance on any information provided by this website is solely at your own risk.


Sep 5, 2008
Home
Search
Powered By HealthLine
New! For timely and trustworth health information, expert advice and much more, visit Breast Cancer Connection
Patient Guide
News
Health Videos
Health Encyclopedia
Health News Archive
Affiliate Information
HealthScout Network
Contact Us
Newsletters
Privacy Policy
Terms of Use

We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service  

To find more information on specific conditions, please visit our partner sites: